Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013)

The primary objective of this trial was to assess the feasibility, toxicity profile, and antitumor activity of gemtuzumab ozogamicin (GO) combined with a chemotherapy remission-induction regimen in adults with untreated high-risk myelodysplastic syndrome (HR-MDS) or secondary acute myeloid leukemia...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Ann Hematol
Main Authors: de Witte, Theo, Suciu, Stefan, Meert, Liv, Halkes, Constantijn, Selleslag, Dominik, Bron, Dominique, Amadori, Sergio, Willemze, Roel, Muus, Petra, Baron, Frédéric
Formato: Artigo
Idioma:Inglês
Publicado: Springer Berlin Heidelberg 2015
Assuntos:
Original Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4604495/
https://ncbi.nlm.nih.gov/pubmed/26410352
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-015-2486-9
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares